Moran Wealth Management LLC Purchases 4,287 Shares of Quest Diagnostics Incorporated $DGX

Moran Wealth Management LLC raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,351 shares of the medical research company’s stock after buying an additional 4,287 shares during the period. Moran Wealth Management LLC owned about 0.10% of Quest Diagnostics worth $21,235,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Key Financial Inc boosted its holdings in Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares during the period. Quattro Advisors LLC purchased a new stake in Quest Diagnostics in the fourth quarter worth $25,000. JFS Wealth Advisors LLC increased its stake in Quest Diagnostics by 114.3% in the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after purchasing an additional 80 shares during the period. Harbor Investment Advisory LLC lifted its position in shares of Quest Diagnostics by 113.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock worth $27,000 after purchasing an additional 83 shares during the last quarter. Finally, DV Equities LLC bought a new stake in shares of Quest Diagnostics during the fourth quarter worth $27,000. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 0.2%

Shares of NYSE DGX opened at $215.35 on Friday. Quest Diagnostics Incorporated has a 1-year low of $164.65 and a 1-year high of $217.41. The business has a fifty day moving average price of $197.41 and a 200 day moving average price of $193.95. The stock has a market capitalization of $23.84 billion, a P/E ratio of 23.80, a price-to-earnings-growth ratio of 2.57 and a beta of 0.58. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The business had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period in the previous year, the company posted $1.94 earnings per share. The firm’s revenue was up 9.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Equities research analysts expect that Quest Diagnostics Incorporated will post 10.72 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Wednesday, July 8th. Quest Diagnostics’s payout ratio is currently 38.01%.

Analysts Set New Price Targets

A number of equities analysts have commented on DGX shares. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a $225.00 price target on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Barclays boosted their price target on Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. UBS Group increased their price objective on Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 22nd. Finally, Evercore set a $225.00 price objective on Quest Diagnostics in a report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics currently has an average rating of “Moderate Buy” and a consensus price target of $216.58.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.